NEXGEL, INC. 8-K

What Happened NexGel, Inc. announced on March 6, 2026 that it entered into an Asset Purchase and Exclusive License Agreement with Celularity, Inc. under which NexGel will acquire and receive an exclusive license to Celularity’s commercial‑stage biomaterials portfolio and certain development‑stage programs (the “Business”). Consideration is up to $35.0 million: a $15.0 million upfront cash payment plus up to $20.0 million in milestone payments tied to net sales targets. The deal includes customary ancillary contracts (e.g., contract manufacturing and a sublease) and is subject to customary closing conditions, including NexGel’s receipt of sufficient financing to pay the $15.0 million upfront.

Key Details

• Agreement date: March 6, 2026; press release announcing the transaction filed March 10, 2026.
• Purchase consideration: up to $35.0 million total ( $15.0M upfront + $20.0M tied to net‑sales milestones ).
• Closing condition: NexGel must obtain financing sufficient to make the $15.0M upfront payment.
• Financing discussions: NexGel is negotiating an equity line of credit with an accredited investor for up to $100 million in common stock purchases, subject to conditions and discounts to market price.

Why It Matters This transaction could expand NexGel’s commercial product offerings and create new revenue opportunities if the licensed products achieve sales. However, the deal is not final until closing conditions are met—notably NexGel securing financing for the upfront payment—which may require issuing new shares. Investors should note the company’s ongoing equity line talks (up to $100M), which could dilute existing shareholders if used. The filing also contains standard forward‑looking disclaimers; the full agreement is attached as an exhibit to the 8‑K for details.